(ANGO) AngioDynamics - Ratings and Ratios

AngioDynamics Inc (NASDAQ:ANGO) is a medical technology company specializing in designing, manufacturing, and selling medical devices for treating peripheral vascular disease, oncology, and surgical settings globally. The companys product portfolio includes atherectomy systems, thrombus management systems, ablation systems, and peripheral products, such as angiographic catheters and guidewires.

Key products include the Auryon Atherectomy system, AlphaVac mechanical thrombectomy system, NanoKnife IRE Ablation System, and VenaCure EVLT system, which cater to various medical needs, including lesion removal, blood clot dissolution, and treatment of superficial venous disease. The companys products are designed to provide minimally invasive solutions for interventional physicians.

From a financial perspective, AngioDynamics has a market capitalization of $397.14M USD, indicating a relatively small-cap stock. The companys forward P/E ratio is 96.15, suggesting high growth expectations. However, the Return on Equity (RoE) is -21.37%, indicating that the company is currently unprofitable. Other key performance indicators (KPIs) to monitor include revenue growth, gross margin, and operating cash flow. As a trading analyst, it is essential to closely watch these metrics to assess the companys financial health and potential for future growth.

To further evaluate AngioDynamics potential, it is crucial to analyze industry trends, competitive landscape, and the companys research and development pipeline. The medical technology industry is highly competitive, and companies must innovate to stay ahead. AngioDynamics product portfolio and R&D efforts should be assessed in the context of the industrys evolving needs and competitor activity.